Descripción de la empresa
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology enterprise dedicated to the discovery and development of engineered T cell therapies specifically designed for patients suffering from autoimmune diseases. The company functions within the broader Healthcare sector, focusing on the specialized Biotechnology industry where innovation in cellular immunology drives therapeutic advancements. With a total market capitalization of $341.76M and an employee count of 154, the firm represents a mid-sized capitalization entity within the biotech landscape. The current market cap indicates that the company possesses significant market interest despite lacking reported revenue figures, a common characteristic for clinical-stage firms where valuation is driven by pipeline potential rather than current sales performance. This scale reflects a company that is resource-intensive, requiring substantial capital to advance its lead product candidate, resecabtagene autoleucel, through clinical development phases before generating commercial income. The absence of annual revenue in the provided data underscores the pre-revenue status typical of entities still navigating the rigorous regulatory and clinical trial processes necessary to bring complex cell therapies to market.
Salud financiera
The financial statements for Cabaletta Bio, Inc. report a Net Income of $-167,856,000 over the trailing twelve-month period, while the EBITDA stands at $-170,595,008, highlighting the heavy operational expenditures inherent in clinical development. The revenue figure is listed as N/A, meaning that the substantial gap between this zero revenue baseline and the significant net losses reveals a cost structure dominated by research and development expenses rather than commercial overheads. Free Cash Flow is reported at $-81,283,128, indicating that the company is burning through its liquidity to fund operations and clinical trials, which limits immediate financial flexibility but is standard for pre-commercial biotechnology ventures. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a valuation characteristic that signifies the company has not yet transitioned to a profitable revenue-generating model where margins can be calculated on sales. On the balance sheet, the company holds $133.60M in cash against $27.10M in debt, resulting in a Debt to Equity ratio of 24.18, which suggests a leverage profile heavily weighted toward equity financing rather than debt obligations. The Current Ratio stands at 2.77, demonstrating a robust short-term liquidity position where current assets significantly exceed current liabilities, providing a comfortable buffer against immediate financial obligations. Return on Equity is -127.0% and Return on Assets is -61.5%, metrics that reveal management is currently deploying capital to generate value through future growth rather than realizing immediate returns on invested equity or assets.
Evaluación de valoración
The valuation metrics for Cabaletta Bio, Inc. include a P/E Ratio (TTM) of N/A and a Forward P/E of -2.19, where the absence of a trailing P/E confirms the lack of earnings while the negative forward P/E reflects market expectations of continued losses or the difficulty in projecting positive earnings in the near term. The Price to Book ratio is 2.75, indicating that the market values the company at a significant premium above its book value, likely due to the high intangible value of its intellectual property and clinical pipeline rather than tangible assets. Price to Sales is N/A and the EV/EBITDA is -1.38, suggesting that traditional revenue-based or earnings-based valuation multiples are not applicable due to the pre-revenue status and negative earnings, requiring investors to rely on alternative metrics like market cap and cash position. The stock has traded between a 52-Week High of $3.78 and a 52-Week Low of $1.01, meaning the current price sits at a specific point within this volatility range that reflects recent market sentiment toward the company's development progress. The Beta value is 3.29, which signifies that the stock price is highly volatile and moves with much greater intensity than the broader market, exposing investors to significant price swings relative to standard market indices.
Growth & Income
The growth metrics show Revenue Growth (YoY) as N/A and Earnings Growth (YoY) as N/A, indicating that the company is not yet generating the consistent positive growth rates required to calculate year-over-year expansion percentages in the traditional sense. As a non-dividend payer with a Dividend Yield of N/A and a Payout Ratio of 0.0%, the company does not distribute earnings to shareholders, as there are no earnings to distribute and the strategy focuses entirely on capital retention. Consequently, the firm reinvests its limited cash reserves and potential future earnings directly into research and development activities to accelerate the clinical progression of its engineered T cell therapies rather than paying out income. The overall growth and income profile is defined by a high-risk, high-reward dynamic where the absence of current revenue growth is offset by the potential for future commercialization once the lead product candidate reaches market approval. This profile aligns with the clinical-stage biotechnology model where value accrual is deferred until regulatory milestones are achieved and commercial sales commence.